How Incretin Drugs Affect the Heart

A review published online on 10 September 2026 in the Canadian Journal of Physiology and Pharmacology takes on a question that has been building for several years: how much of the cardiovascular benefit seen with incretin receptor agonists actually comes from lowering blood sugar^[1]? The authors, based at the University of Kragujevac in Serbia, pulled together mediation analyses from major cardiovascular outcomes trials and reported that glycaemic improvement accounts for less than 15 to 20 percent of the reduction in major adverse cardiovascular events these drugs produce^[1]. The remainder, the review argues, comes from a mix of weight reduction, changes to blood lipids, lower blood pressure, reduced systemic inflammation, and direct effects on the heart muscle itself.

What the review actually covers

This is a narrative review, not a new clinical trial or a formal meta-analysis. It surveys published evidence across three generations of incretin-based drugs: single GLP-1 receptor agonists, dual GLP-1 and GIP agonists such as tirzepatide, and newer triple GLP-1, GIP, and glucagon receptor agonists such as retatrutide. The organising idea is that as this drug class has added receptor targets, researchers have also been documenting cardiovascular effects that look separate from what glucose control or weight loss alone would predict^[1].

The heart benefit is not mainly about blood sugar

The mediation-analysis finding is the headline claim, and it reframes how to read the class's cardiovascular data. Trial evidence suggests the converging mechanisms include weight reduction, lipid remodelling, blood-pressure reduction, and lower systemic inflammation^[1]. The review also describes cellular-level work showing that incretin receptor signalling preserves mitochondrial function in heart cells, activates antioxidant defences, and blocks several pathways that would otherwise lead to cardiomyocyte death^[1]. None of this replaces glucose control as a clinical goal in type-2 diabetes. It does suggest the cardiovascular story is broader than the glycaemic one.

What tirzepatide and retatrutide add to the picture

The review cites cardiac magnetic resonance evidence from the SUMMIT programme showing reverse left ventricular remodelling with tirzepatide in adults with obesity-related heart failure with preserved ejection fraction^[1]. That builds on the primary SUMMIT trial result, which reported a 38 percent reduction in the composite of cardiovascular death or worsening heart-failure events in 731 adults over a median 104 weeks^[2]. Separately, the review points to recent work in isolated human atrial tissue finding direct positive inotropic effects, meaning a stronger heart-muscle contraction, from both single GLP-1 receptor agonists and the triple agonist retatrutide^[1]. Retatrutide's broader clinical dataset is still limited to Phase 2 obesity and diabetes trials, where the drug produced substantial weight loss over 36 to 48 weeks^[3]; a dedicated cardiovascular outcomes trial for retatrutide, called TRIUMPH-Outcomes, is running but is not expected to report until 2029.

What is established versus what is still emerging

The class-wide reduction in major adverse cardiovascular events across large outcomes trials is reasonably well established at this point, which is precisely why the review's mediation analysis is interesting: the benefit is real, but the mechanism behind it is less settled than the glucose-control story implies^[1]. The tissue-level and cellular mechanisms are newer and rest on a thinner evidence base: isolated human tissue preparations and mediation statistics, not large randomised outcome data specific to those mechanisms. For tirzepatide, SUMMIT is a real outcomes trial in a specific population (obesity-related HFpEF); a broader cardiovascular outcomes trial in adults with obesity but without diabetes has not yet reported^[2]. For retatrutide, the cardiovascular case rests almost entirely on mechanistic and surrogate findings so far, with the outcomes evidence still years away.

What the review does not tell us

A narrative review reflects the authors' reading of the literature rather than a systematic search with a formal risk-of-bias assessment, so it is worth being honest about what that means here. The evidence it draws on spans very different strengths of proof, from cellular and isolated-tissue experiments to large randomised outcomes trials, and the review does not weight or grade those sources the way a systematic review would^[1]. It also does not generate any new patient data itself; every claim traces back to previously published work. And the authors are explicit that Phase 3 outcomes data from the TRIUMPH programme for the triple-agonist tier ^[1], which is a direct acknowledgement that the most important cardiovascular questions about retatrutide are not yet answered.

What this means for readers

If you are following the incretin-drug class because of a diabetes or obesity diagnosis, the practical takeaway is narrow: the cardiovascular benefit documented in large trials for drugs like tirzepatide does not appear to be a side effect of glucose control or weight loss alone, and researchers are actively mapping additional pathways. That is a mechanistic finding, not a reason to change how any drug in this class is prescribed or used. Retatrutide remains investigational, with no approved indication anywhere, and its cardiovascular data so far is early and largely mechanistic rather than outcomes-based. Anyone weighing treatment options, current or future, should have that conversation with a clinician who knows their full medical history rather than drawing conclusions from a single review article.